Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$620.04M$620.04M+13.7% vs Q3 2022 Net Income$9.68M$9.68MN/M vs Q3 2022 EPS Diluted$0.06$0.06N/M vs Q3 2022 Gross Profit$232,531,000+19.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$81,387,000−13.0% Free Cash Flowderived$69,727,000−6.4% Margins · derivedGross margin37.5%+1.9 pt vs Q3 2022
Operating margin12.2%+4.1 pt vs Q3 2022
Net margin1.6%+3.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end